Jung Shin Byun, Ph.D.
Jung Shin Byun, Ph.D.
Staff Scientist

Center for Cancer Research
National Cancer Institute

Building 37, Room 1042
Bethesda, MD 20892
301-435-2890

Dr. Jung S. Byun received her Ph.D. in chemistry and biochemistry at the University of Maryland in College Park. She pursued postdoctoral studies with Dr. Kevin Gardner at the NCI Center for Cancer Research. During her postdoctoral residency, she carried out studies to define how histone acetyltransferase, p300 and the elongation factor, ELL, work in concert to control eukaryotic transcription by demonstrating the role of dynamic bookmarking by p300 RNA polymerase II complexes in transcriptional memory (Byun et al., Proc Natl Acad Sci USA 2009) and also discovered a new role for ELL (Eleven-nineteen Lysine rich Leukemia protein); that it is required for early elongation and facilitating pol II pause site entry (Byun et al., Nature Comm 2012). Dr. Byun is currently a staff scientist in Dr. Kevin Gardner's laboratory. The lab's research interests focus on defining other potential transcription regulatory targets important in mammalian cancer cell biology that define a molecular link between metabolic imbalance and breast cancer.

Areas of Expertise
breast cancer

We are interested in defining the mechanism and roles of the metabolic regulators in the control of transcription during phenotypic reprogramming in breast cancer. We want to investigate the profile of genome-wide changes in the metabolic regulators associated with epigenetic control and histone modification during the phenotypic transitions in mammary epithelial cells. It has been known that C-terminal binding protein (CTBP) is a dimeric nuclear protein involved in important functions in transcriptional regulation of mammalian cells. In the presence of NADH, CTBP recruits a variety of epigenetic regulators including histone deacetylase (HDAC), lysine specific demethylase (LSD), and histone methyltransferease (G9a) to the gene proximal promoter by interacting with DNA sequence-specific binding proteins. This provides a potential link between metabolism and control of the epigenetic landscape of the nuclei.

We have recently shown that CTBP recruits many negative regulators, including HDAC, in the presence of NADH to the BRCA1 promoter to turn off gene expression; however, under conditions of caloric restriction or caloric consumption, as with estrogen induction, the negative regulators are dismissed from the promoter with CTBP to allow an exchange for positive regulators containing p300/CBP complexes. This antagonism between CTBP and p300 is played out in many genes. Our recent genome-wide survey in MCF-7 reveals that CTBP regulates many different gene pathways that drive major hallmarks of cancer including genome instability, epithelial to mesenchymal transition, and tumor initiation cells/stem cell pathways. We will continue to investigate the new roles of CTBP and metabolic imbalance in breast cancer invasion and metastasis using murine models for invasion and metastasis and we will characterize the impact of CTBP in developmental windows associated with increased breast cancer risk using patient samples.

Selected Publications
  1. Byun JS, Wong MM, Cui W, Idelman G, Li Q, De Siervi A, Bilke S, Haggerty CM, Player A, Wang YH, Thirman MJ, Kaberlein JJ, Petrovas C, Koup RA, Longo D, Ozato K, Gardner K.
    Proc. Natl. Acad. Sci. U.S.A.. 106: 19286-91, 2009. [ Journal Article ]
  2. Byun JS, Gardner K.
    Int J Cell Biol. 2013: 647975, 2013. [ Journal Article ]
  3. Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C, Khramtsova G, Cheng F, Perou CM, Miller CR, Raab R, Olopade OI, Gardner K.
    Nat Commun. 4: 1449, 2013. [ Journal Article ]
  4. Byun JS, Gardner K.
    Am. J. Pathol.. 182: 1055-64, 2013. [ Journal Article ]
  5. Byun JS, Fufa TD, Wakano C, Fernandez A, Haggerty CM, Sung MH, Gardner K.
    Nat Commun. 3: 633, 2012. [ Journal Article ]

Dr. Jung S. Byun received her Ph.D. in chemistry and biochemistry at the University of Maryland in College Park. She pursued postdoctoral studies with Dr. Kevin Gardner at the NCI Center for Cancer Research. During her postdoctoral residency, she carried out studies to define how histone acetyltransferase, p300 and the elongation factor, ELL, work in concert to control eukaryotic transcription by demonstrating the role of dynamic bookmarking by p300 RNA polymerase II complexes in transcriptional memory (Byun et al., Proc Natl Acad Sci USA 2009) and also discovered a new role for ELL (Eleven-nineteen Lysine rich Leukemia protein); that it is required for early elongation and facilitating pol II pause site entry (Byun et al., Nature Comm 2012). Dr. Byun is currently a staff scientist in Dr. Kevin Gardner's laboratory. The lab's research interests focus on defining other potential transcription regulatory targets important in mammalian cancer cell biology that define a molecular link between metabolic imbalance and breast cancer.

Summary

Dr. Jung S. Byun received her Ph.D. in chemistry and biochemistry at the University of Maryland in College Park. She pursued postdoctoral studies with Dr. Kevin Gardner at the NCI Center for Cancer Research. During her postdoctoral residency, she carried out studies to define how histone acetyltransferase, p300 and the elongation factor, ELL, work in concert to control eukaryotic transcription by demonstrating the role of dynamic bookmarking by p300 RNA polymerase II complexes in transcriptional memory (Byun et al., Proc Natl Acad Sci USA 2009) and also discovered a new role for ELL (Eleven-nineteen Lysine rich Leukemia protein); that it is required for early elongation and facilitating pol II pause site entry (Byun et al., Nature Comm 2012). Dr. Byun is currently a staff scientist in Dr. Kevin Gardner's laboratory. The lab's research interests focus on defining other potential transcription regulatory targets important in mammalian cancer cell biology that define a molecular link between metabolic imbalance and breast cancer.

Areas of Expertise
breast cancer

Research

We are interested in defining the mechanism and roles of the metabolic regulators in the control of transcription during phenotypic reprogramming in breast cancer. We want to investigate the profile of genome-wide changes in the metabolic regulators associated with epigenetic control and histone modification during the phenotypic transitions in mammary epithelial cells. It has been known that C-terminal binding protein (CTBP) is a dimeric nuclear protein involved in important functions in transcriptional regulation of mammalian cells. In the presence of NADH, CTBP recruits a variety of epigenetic regulators including histone deacetylase (HDAC), lysine specific demethylase (LSD), and histone methyltransferease (G9a) to the gene proximal promoter by interacting with DNA sequence-specific binding proteins. This provides a potential link between metabolism and control of the epigenetic landscape of the nuclei.

We have recently shown that CTBP recruits many negative regulators, including HDAC, in the presence of NADH to the BRCA1 promoter to turn off gene expression; however, under conditions of caloric restriction or caloric consumption, as with estrogen induction, the negative regulators are dismissed from the promoter with CTBP to allow an exchange for positive regulators containing p300/CBP complexes. This antagonism between CTBP and p300 is played out in many genes. Our recent genome-wide survey in MCF-7 reveals that CTBP regulates many different gene pathways that drive major hallmarks of cancer including genome instability, epithelial to mesenchymal transition, and tumor initiation cells/stem cell pathways. We will continue to investigate the new roles of CTBP and metabolic imbalance in breast cancer invasion and metastasis using murine models for invasion and metastasis and we will characterize the impact of CTBP in developmental windows associated with increased breast cancer risk using patient samples.

Publications

Selected Publications
  1. Byun JS, Wong MM, Cui W, Idelman G, Li Q, De Siervi A, Bilke S, Haggerty CM, Player A, Wang YH, Thirman MJ, Kaberlein JJ, Petrovas C, Koup RA, Longo D, Ozato K, Gardner K.
    Proc. Natl. Acad. Sci. U.S.A.. 106: 19286-91, 2009. [ Journal Article ]
  2. Byun JS, Gardner K.
    Int J Cell Biol. 2013: 647975, 2013. [ Journal Article ]
  3. Di LJ, Byun JS, Wong MM, Wakano C, Taylor T, Bilke S, Baek S, Hunter K, Yang H, Lee M, Zvosec C, Khramtsova G, Cheng F, Perou CM, Miller CR, Raab R, Olopade OI, Gardner K.
    Nat Commun. 4: 1449, 2013. [ Journal Article ]
  4. Byun JS, Gardner K.
    Am. J. Pathol.. 182: 1055-64, 2013. [ Journal Article ]
  5. Byun JS, Fufa TD, Wakano C, Fernandez A, Haggerty CM, Sung MH, Gardner K.
    Nat Commun. 3: 633, 2012. [ Journal Article ]

Biography

Dr. Jung S. Byun received her Ph.D. in chemistry and biochemistry at the University of Maryland in College Park. She pursued postdoctoral studies with Dr. Kevin Gardner at the NCI Center for Cancer Research. During her postdoctoral residency, she carried out studies to define how histone acetyltransferase, p300 and the elongation factor, ELL, work in concert to control eukaryotic transcription by demonstrating the role of dynamic bookmarking by p300 RNA polymerase II complexes in transcriptional memory (Byun et al., Proc Natl Acad Sci USA 2009) and also discovered a new role for ELL (Eleven-nineteen Lysine rich Leukemia protein); that it is required for early elongation and facilitating pol II pause site entry (Byun et al., Nature Comm 2012). Dr. Byun is currently a staff scientist in Dr. Kevin Gardner's laboratory. The lab's research interests focus on defining other potential transcription regulatory targets important in mammalian cancer cell biology that define a molecular link between metabolic imbalance and breast cancer.